US 12,391,754 B2
Fusion protein of single domain antibody and procoagulant
Qi Li, Lawrenceville, GA (US); and Huafei Zou, Norcross, GA (US)
Assigned to Beijing Neoletix Biological Technology Co., Ltd., Beijing (CN)
Filed by Beijing Neoletix Biological Technology Co., Ltd., Beijing (CN)
Filed on Oct. 22, 2021, as Appl. No. 17/452,033.
Application 17/452,033 is a continuation of application No. PCT/US2020/029599, filed on Apr. 23, 2020.
Claims priority of provisional application 62/844,610, filed on May 7, 2019.
Prior Publication US 2022/0041716 A1, Feb. 10, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 7/04 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 7/04 (2018.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/565 (2013.01); C07K 2319/33 (2013.01)] 10 Claims
 
1. A single domain antibody against triggering receptors expressed on myeloid cells (TREM)-like transcript-1 (TLT-1), comprising:
(a) CDR1 being SEQ ID NO: 6, CDR2 being SEQ ID NO: 32, CDR3 being SEQ ID NO: 43;
(b) CDR1 being SEQ ID NO: 8, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 44;
(c) CDR1 being SEQ ID NO: 3, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 41;
(d) CDR1 being SEQ ID NO: 3, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 42;
(e) CDR1 being SEQ ID NO: 1, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 40;
(f) CDR1 being SEQ ID NO: 25, CDR2 being SEQ ID NO: 35, CDR3 being SEQ ID NO: 45;
(g) CDR1 being SEQ ID NO: 3, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 46;
(h) CDR1 being SEQ ID NO: 11, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 47;
(i) CDR1 being SEQ ID NO: 16, CDR2 being SEQ ID NO: 31, CDR3 being SEQ ID NO: 50; or
(j) CDR1 being SEQ ID NO: 25, CDR2 being SEQ ID NO: 35, CDR3 being SEQ ID NO: 59.